This Plain Language Summary of Publication article (PLSP) from Pain Management outlines the DELIVER study (2020-2022) that tested eptinezumab (VYEPTI®) for migraine prevention in adults who had failed 2-4 previous treatments. The research evaluated both effectiveness and safety over 1.5 years, focusing on reducing monthly migraine days rather than complete elimination, which could potentially decrease patients’ need for acute symptom-relief medications.

Visit the site using this link to read the article.

This PLSP is based on two articles called ‘Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial’ published in The Lancet Neurology and ‘Long-term effectiveness of eptinezumab in patients with migraine and prior preventive treatment failures: extension of a randomized controlled trial’ and was published in The Journal of Headache and Pain.

Visit The Lancet using the link to read the original article.

Visit the BMC using the link to read the original article.